Severe acute respiratory syndrome-related coronavirus

Diazyme Laboratories, Inc. Receives FDA EUA for COVID-19 Antibody Test

Thursday, July 9, 2020 - 1:32am

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test.

Key Points: 
  • SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test.
  • The Diazyme IgG test is run on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.
  • Diazyme has been at the forefront of the development effort to bring timely, high quality COVID-19 serology (antibody) tests during the public health emergency.
  • The fully automated Diazyme DZ-Lite SARS-CoV-2 IgG test exceeds sensitivity and specificity requirements for laboratory run serology tests.

Absolute Antibody and University of Zurich Collaborate to Offer Synthetic Nanobodies Against SARS-CoV-2 Receptor Binding Domain

Wednesday, July 8, 2020 - 12:00pm

REDCAR, U.K., July 8, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • REDCAR, U.K., July 8, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.
  • The laboratory of Markus Seeger at University of Zurich developed a rapid in vitro selection platform to generate synthetic nanobodies, known as sybodies, against the receptor binding domain (RBD) of SARS-CoV-2.
  • Absolute Antibody recombinantly produces the SARS-CoV-2 synthetic nanobodies for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
  • In addition, Absolute Antibody has used antibody engineering to fuse the nanobodies to Fc domains in different species, isotypes and subtypes.

LI-COR Near-Infrared Assays and Technology Offer Insight to Coronavirus Researchers

Tuesday, July 7, 2020 - 4:57pm

Key to this process are quantifiable assays that provide robust data for all aspects of research.

Key Points: 
  • Key to this process are quantifiable assays that provide robust data for all aspects of research.
  • LI-CORBiosciences continues to support virology researchers with products, tools, and services to better understand SARS-CoV-2 and other viruses.
  • Traditionally, infectivity of viruses that exhibit cytopathic effect (CPE) has been characterized using plaque assays.
  • From academic discovery through preclinical validation, whether characterizing a pathway or validating a therapeutic candidate, LI-COR technology helps move research through the development process.

Proven Pharma Named Exclusive Distributor of the Clungene® SARS-CoV-2 IgG/IgM Rapid Serology Test

Tuesday, July 7, 2020 - 3:07pm

The test has been submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and is awaiting approval.

Key Points: 
  • The test has been submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and is awaiting approval.
  • The FDA is currently allowing the test to be made available in the U.S. as the agency reviews its EUA application.
  • The FDA is allowing Clungene SARS-CoV-2 IgG/IgM Rapid Serology Test to be made available under its new policy dated May 4, 2020.
  • Proven Pharma has performed multiple site visits of the Hangzhou Clongene Biotech facilities for quality assurance and supply chain efficiencies.

Nice-Pak Disinfectant Products Demonstrate Efficacy Against Virus Causing COVID-19

Tuesday, July 7, 2020 - 2:21pm

9480-5) demonstrated efficacy against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • 9480-5) demonstrated efficacy against SARS-CoV-2, the virus that causes COVID-19.
  • Nice-Pak's wipes are sold under the Grime Boss brand, as well as many popular private labels.
  • If approved, Nice-Pak will update its products' labels, providing consumers with a proven effective solution to kill the SARS-CoV-2 virus, when used according to label instructions.
  • Nice-Pak produces high demand essential cleaning products including Disinfecting Wipes, Antibacterial Hand Wipes, and Personal Hygiene Wipes.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm

Wednesday, July 8, 2020 - 9:00pm

On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.

Key Points: 
  • On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.
  • On that same day, Defendant Henry Ji, founder and Chief Executive Officer of Sorrento referred to Sorrentos breakthrough as a cure.
  • On this news, Sorrento shares closed at $5.70 per share on May 20, 2020, representing a decline of $4.30, or 43.0%, from the Class Period high.
  • For more information on the Hebron Technology class action go to: https://bespc.com/HEBT
    About Bragar Eagel & Squire, P.C.

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Tuesday, July 7, 2020 - 1:30pm

https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS), a member of the Journal of the American College of Cardiology (JACC) family of journals.

Key Points: 
  • https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS), a member of the Journal of the American College of Cardiology (JACC) family of journals.
  • The paper provides new information on mechanisms involved in host cell binding and entry of the SARS-CoV-2 in the human heart.
  • Moreover, mechanisms or constituents other than ACE2 that could participate in CoV2 host cell binding and internalization had not been previously investigated in remodeled human left ventricles (LVs).
  • The University of Colorado Anschutz Medical Campusis a world-class medical destination at the forefront of transformative science, medicine, education, and patient care.

In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial

Tuesday, July 7, 2020 - 1:00pm

Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Key Points: 
  • Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.
  • Brilacidin also appears to be showing greatest efficacy in testing when administered as a pre-treatment (virus pre-incubated with Brilacidin prior to infection), in addition to being present during and post-infection.
  • The higher the SI ratio, the more effective and safe a drug has the potential to be in the clinic.
  • Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).

Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines

Wednesday, July 8, 2020 - 10:00am

Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza.

Key Points: 
  • Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza.
  • Osivax is deploying the same approach toward a universal coronavirus vaccine to protect against the current virus, SARS-Cov-2, and future coronavirus strains.
  • The European Innovation Council (EIC) has selected Osivax to receive up to EUR 17.5M in blended financing with grant and equity support.
  • Additionally, Bpifrance has pledged EUR 15.1M as part of a Projets Structurants Pour la Comptitivit (PSPC) COVID-19 grant to support Osivax coronavirus vaccine program.

Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma

Tuesday, July 7, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.
  • The investigators are currently conducting a subsequent study to assess the ability of the INTERCEPT Blood System to inactivate SARS-CoV-2 in platelet components.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.